Published in Blood on March 03, 2005
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res (2007) 1.25
Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol (2010) 1.13
Structural interplay between germline interactions and adaptive recognition determines the bandwidth of TCR-peptide-MHC cross-reactivity. Nat Immunol (2015) 1.03
Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology (2008) 1.03
Hematopoietic stem cells for cancer immunotherapy. Immunol Rev (2014) 0.95
Directed differentiation of induced pluripotent stem cells towards T lymphocytes. J Vis Exp (2012) 0.87
Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol Immunother (2010) 0.86
Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother (2012) 0.85
How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer. Front Immunol (2012) 0.79
Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci Rep (2016) 0.76
Cloning and expression of human membrane-bound and soluble engineered T cell receptors for immunotherapy. J Biomed Biotechnol (2006) 0.75
A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. Oncotarget (2016) 0.75
Costimulation with anti-cluster of differentiation 3 and anti-cluster of differentiation 28 reduces the activity of mucin 1-stimulated human mononuclear cells. Oncol Lett (2015) 0.75
TGFα-PE38 enhances cytotoxic T-lymphocyte killing of breast cancer cells. Oncol Lett (2014) 0.75
Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer. Oncoimmunology (2013) 0.75
Basic local alignment search tool. J Mol Biol (1990) 659.07
Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A (1991) 119.63
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Raster3D: photorealistic molecular graphics. Methods Enzymol (1997) 27.30
Cancer statistics, 2003. CA Cancer J Clin (2003) 13.46
Innate immunity: the virtues of a nonclonal system of recognition. Cell (1997) 9.42
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol (2002) 7.78
An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science (1996) 5.93
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature (2001) 4.93
Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med (1999) 4.92
LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol (1994) 3.47
Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res (2001) 2.90
Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer. Nature (1985) 2.84
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol (2001) 2.79
Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med (1996) 2.73
Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A (1989) 2.11
Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet (1993) 1.51
Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J Immunol (2001) 1.35
A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int J Cancer (1989) 1.34
Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells. Proc Natl Acad Sci U S A (2002) 1.22
High-efficiency expression and solubilization of functional T cell antigen receptor heterodimers. Science (1992) 1.18
Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. Blood (2000) 1.16
Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood (1998) 1.14
Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol (2003) 1.04
Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res (2003) 1.01
Functional three-domain single-chain T-cell receptors. Proc Natl Acad Sci U S A (1994) 1.01
Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. J Immunol (1998) 1.00
Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res (1993) 0.99
Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (1997) 0.98
Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope. J Biomol Struct Dyn (1995) 0.95
Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant (2000) 0.93
Tumour MHC class I downregulation and immunotherapy (Review). Oncol Rep (2003) 0.92
Selection of T cell receptor variable gene-encoded amino acids on the third binding site loop: a factor influencing variable chain selection in a T cell response. Eur J Immunol (1995) 0.84
Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant (2000) 0.84
High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant (1998) 0.80
Specific and effective T-cell recognition of cells transfected with a truncated human mucin cDNA. Ann N Y Acad Sci (1993) 0.80
High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplant (1997) 0.79
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.43
MUC1 immunobiology: from discovery to clinical applications. Adv Immunol (2004) 1.79
Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila) (2010) 1.75
De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. Antimicrob Agents Chemother (2005) 1.70
MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res (2008) 1.66
An HSV vector system for selection of ligand-gated ion channel modulators. Nat Methods (2007) 1.57
Effects of membrane lipids on ion channel structure and function. Cell Biochem Biophys (2003) 1.43
MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) (2012) 1.39
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother (2004) 1.36
Immune response as a biomarker for cancer detection and a lot more. N Engl J Med (2005) 1.35
IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol (2011) 1.32
T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res (2005) 1.24
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther (2008) 1.22
Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. J Immunol (2007) 1.21
Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol (2011) 1.16
Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev (2010) 1.15
Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis (2009) 1.11
Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.11
Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol (2005) 1.09
Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol (2002) 1.07
MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-κB p65 and binding to cytokine promoters: importance of extracellular domain. J Biol Chem (2011) 1.06
Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas (2010) 1.05
Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clin Exp Metastasis (2002) 1.03
Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes Control (2010) 1.03
Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res (2006) 1.03
Tenascin cytotactin epidermal growth factor-like repeat binds epidermal growth factor receptor with low affinity. J Cell Physiol (2007) 1.02
Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol Chem (2009) 1.00
Measuring the maturity of the fast-spiking interneuron transcriptional program in autism, schizophrenia, and bipolar disorder. PLoS One (2012) 1.00
Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res (2010) 0.99
MUC1 immunotherapy is here to stay. Expert Opin Biol Ther (2012) 0.98
Theoretical studies of the M2 transmembrane segment of the glycine receptor: models of the open pore structure and current-voltage characteristics. Biophys J (2005) 0.98
Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J Immunol (2007) 0.98
Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine. J Neurochem (2008) 0.98
Homology modeling and molecular dynamics simulations of the alpha1 glycine receptor reveals different states of the channel. Proteins (2007) 0.97
Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci U S A (2009) 0.97
Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis (2007) 0.95
Molecular dynamics simulations of ethanol binding to the transmembrane domain of the glycine receptor: implications for the channel potentiation mechanism. Proteins (2008) 0.94
Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol (2008) 0.94
Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis (2004) 0.94
Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration. Oncotarget (2013) 0.92
Incidence rate of breast cancer in young women. JAMA (2013) 0.91
Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol Immunol (2008) 0.91
Aberrant expression of MUC1 mucin in pediatric inflammatory bowel disease. Pediatr Dev Pathol (2010) 0.91
Amylin receptor signaling in the ventral tegmental area is physiologically relevant for the control of food intake. Neuropsychopharmacology (2013) 0.90
Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology (2003) 0.90
Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides. Mol Cancer Ther (2004) 0.89
Probing the topology of the glycine receptor by chemical modification coupled to mass spectrometry. Biochemistry (2002) 0.89
Calcium plays a critical role in determining the acetylcholine receptor-clustering activities of alternatively spliced isoforms of Agrin. J Biol Chem (2003) 0.89
Neuroproteomics: expression profiling of the brain's proteomes in health and disease. Neurochem Res (2004) 0.89
Mice with a melanocortin 1 receptor mutation have a slightly greater minimum alveolar concentration than control mice. Anesthesiology (2004) 0.88
Cancer immunology. Curr Opin Immunol (2011) 0.87
Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol Immunol (2009) 0.86
Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol Immunother (2010) 0.86
Homology modeling and molecular dynamics simulations of the glycine receptor ligand binding domain. Proteins (2007) 0.86
Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Semin Immunol (2010) 0.86
DNA vaccines for cancer too. Cancer Immunol Immunother (2005) 0.85
Human papillomavirus vaccine for cancer prevention. N Engl J Med (2009) 0.84
Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen. Oncoimmunology (2012) 0.84
Cancer vaccines: a promising cancer therapy against all odds. Future Oncol (2007) 0.84
Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother (2012) 0.83
Mapping of equine lentivirus receptor 1 residues critical for equine infectious anemia virus envelope binding. J Virol (2007) 0.83
Tumor antigens and tumor antigen discovery. Cancer Treat Res (2005) 0.83
Overexpression and functional characterization of the extracellular domain of the human alpha1 glycine receptor. Biochemistry (2008) 0.83
Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann N Y Acad Sci (2005) 0.83
Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53 (-/-) mice. Ann N Y Acad Sci (2009) 0.82
Tumor antigen-based immunotherapy and immunoprevention of cancer. Int Arch Allergy Immunol (2006) 0.82
AACR Cancer Progress Report 2012. Clin Cancer Res (2012) 0.82
Pulsed electron spin resonance resolves the coordination site of Cu²(+) ions in α1-glycine receptor. Biophys J (2010) 0.81
HSV delivery of a ligand-regulated endogenous ion channel gene to sensory neurons results in pain control following channel activation. Mol Ther (2010) 0.81
Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Res (2006) 0.80
Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy. Cancer Immunol Immunother (2008) 0.79
Constitutive release of powerful antioxidant-scavenging activity by hepatic stellate cells: protection of hepatocytes from ischemia/reperfusion injury. Liver Transpl (2010) 0.79
Electrospray ionization and collision induced dissociation mass spectrometry of primary fatty acid amides. Anal Chem (2012) 0.79
Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells. Oncoimmunology (2013) 0.78
Tumor immunology at the service of cancer immunotherapy. Curr Opin Immunol (2004) 0.78
Mucins in gastrointestinal cancers. Cancer Chemother Biol Response Modif (2003) 0.78
β-Amyloid and neprilysin computational studies identify critical residues implicated in binding specificity. J Chem Inf Model (2014) 0.77
Preventive immunization of aged and juvenile non-human primates to β-amyloid. J Neuroinflammation (2012) 0.77
Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance. Cancer Immunol Res (2013) 0.77
Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas. Ann N Y Acad Sci (2013) 0.77
Asparagine of z8 insert is critical for the affinity, conformation, and acetylcholine receptor-clustering activity of neural agrin. J Biol Chem (2010) 0.77
Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes. J Immunol (2013) 0.77
Early in vivo signaling profiles in MUC1-specific CD4(+) T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology (2013) 0.77
Computational prediction of ion permeation characteristics in the glycine receptor modified by photo-sensitive compounds. J Comput Aided Mol Des (2008) 0.77
Metabolism, physiology, and analyses of primary fatty acid amides. Chem Rev (2013) 0.76
Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigen. J Immunol (2013) 0.76
In vitro interaction of the glycine receptor with the leptin receptor. Physiol Behav (2002) 0.76
Cloning and expression of human membrane-bound and soluble engineered T cell receptors for immunotherapy. J Biomed Biotechnol (2006) 0.75
Generation of a microglial developmental index in mice and in humans reveals a sex difference in maturation and immune reactivity. Glia (2018) 0.75
Cancer vaccines: emphasis on pediatric cancers. Curr Pharm Des (2010) 0.75
Five-year, disease-free survival after repeat palliative multimodality therapy in a patient with recurrent metastatic bladder cancer. ScientificWorldJournal (2007) 0.75
Return to Work of Cancer Survivors. Oncol Res Treat (2017) 0.75